129 related articles for article (PubMed ID: 35032074)
41. [Role of prostate fossa ultrasonography in the diagnosis of local recurrence after radical prostatectomy in case of PSA failure].
Roscigno M; Scattoni V; Raber M; Consonni P; Montorsi F; Pasta A; Bertini R; Colombo R; Da Pozzo L; Freschi M; Rigatti P
Arch Ital Urol Androl; 2002 Dec; 74(4):304-8. PubMed ID: 12508759
[TBL] [Abstract][Full Text] [Related]
42. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
[TBL] [Abstract][Full Text] [Related]
43. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.
Andersen MK; Rise K; Giskeødegård GF; Richardsen E; Bertilsson H; Størkersen Ø; Bathen TF; Rye M; Tessem MB
Sci Rep; 2018 Sep; 8(1):14269. PubMed ID: 30250137
[TBL] [Abstract][Full Text] [Related]
44. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
45. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.
Kong D; Heath E; Chen W; Cher ML; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH
PLoS One; 2012; 7(3):e33729. PubMed ID: 22442719
[TBL] [Abstract][Full Text] [Related]
46. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using
Nehra A; Parker WP; Haloi R; Park SS; Mynderse LA; Lowe VJ; Davis BJ; Quevedo JF; Johnson GB; Kwon ED; Karnes RJ
J Urol; 2018 Mar; 199(3):726-733. PubMed ID: 28916273
[TBL] [Abstract][Full Text] [Related]
47. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
48. Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer.
Zhao HW; Li J; Cao JZ; Lin J; Wang Z; Lv JY; Wei JH; Chen ZH; Yao HH; Pan YH; Gao ZL; Luo JH; Chen W; Shi L; Fang Y
BMC Urol; 2020 Jul; 20(1):100. PubMed ID: 32677927
[TBL] [Abstract][Full Text] [Related]
49. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
50. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ
Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374
[TBL] [Abstract][Full Text] [Related]
51. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
52. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
53. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
54. Role of systematic ultrasound-guided staging biopsies in predicting extraprostatic extension and seminal vesicle invasion in men with prostate cancer.
Okihara K; Kamoi K; Lane RB; Evans RB; Troncoso P; Babaian RJ
J Clin Ultrasound; 2002; 30(3):123-31. PubMed ID: 11948567
[TBL] [Abstract][Full Text] [Related]
55. Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis.
Panach-Navarrete J; González-Marrachelli V; Morales-Tatay JM; García-Morata F; Sales-Maicas MÁ; Monleón-Salvado D; Martínez-Jabaloyas JM
Prostate; 2024 May; 84(6):549-559. PubMed ID: 38212952
[TBL] [Abstract][Full Text] [Related]
56. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
57. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.
Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Aoki M; Takai Y
World J Surg Oncol; 2014 Apr; 12():134. PubMed ID: 24885947
[TBL] [Abstract][Full Text] [Related]
58. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
59. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.
Baco E; Ukimura O; Rud E; Vlatkovic L; Svindland A; Aron M; Palmer S; Matsugasumi T; Marien A; Bernhard JC; Rewcastle JC; Eggesbø HB; Gill IS
Eur Urol; 2015 Apr; 67(4):787-94. PubMed ID: 25240973
[TBL] [Abstract][Full Text] [Related]
60. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
Breeuwsma AJ; Rybalov M; Leliveld AM; Pruim J; de Jong IJ
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
